Hereditary Angioedema (HAE) is a rare, genetic disorder characterised by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. Currently available treatment options include life-long therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week, or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur.
Company
Intellia Therapeutics
